Quantum BioPharma Ltd.(QNTM)Earnings, Financials & Key RatiosQuantum BioPharma Ltd. (QNTM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, highlighted by a current ratio of 0.63 and a dwindling cash balance of $4.4 million, suggests a high probability of further shareholder dilution or insolvency.
Quantum BioPharma Ltd. (QNTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Quantum BioPharma Ltd. (QNTM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $3.06vs $0.49-524.0% | —vs $4M |
| Q2 2026 | Mar 26, 2026 | $0.71vs $1.02+30.5% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $1.25vs $0.20-525.0% | —vs $889,591 |
| Q3 2025 | Aug 6, 2025 | $3.23vs $0.17-1800.0% | — |
Recent stock market news and headlines for Quantum BioPharma Ltd. (QNTM)
AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM) (CSE: QNTM).
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Key metrics vs top competitors for Quantum BioPharma Ltd. (QNTM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.44 | $15.44M | -0.42 | — | — | -337.02% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $1.97 | $38.76M | -1.41 | — | — | -318.08% | — | |
| $3.95 | $68.19M | -2.94 | — | -1070.26% | — | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $12.84 | $1.23B | -4.17 | — | — | -151.02% | — |
Quantum BioPharma Ltd. (QNTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when QNTM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Quantum BioPharma Ltd. (QNTM) stock FAQ — growth, dividends, profitability & financials explained
Quantum BioPharma Ltd. (QNTM) reported a net loss of $31.0M for fiscal year 2025.
Quantum BioPharma Ltd. (QNTM) has a return on equity (ROE) of -337.0%. Negative ROE indicates the company is unprofitable.
Quantum BioPharma Ltd. (QNTM) had negative free cash flow of $5.6M in fiscal year 2025, likely due to heavy capital investments.
